Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P838 | DOI: 10.1530/endoabs.35.P838

ECE2014 Poster Presentations Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) (108 abstracts)

Clinical features and therapeutic outcomes of acromegaly during the recent 5 years: single centre experience

Agne Abraitiene 1, & Vaidotas Urbanavicius 1,

1Vilnius University Hospital Santariskiu klinikos, Vilnius, Lithuania; 2Vilnius University Faculty of Medicine, Vilnius, Lithuania.

Introduction: The purpose of this study was to characterize management and outcomes of patients with acromegaly seen in single centre in Lithuania.

Methods: The study involved retrospective data collection from charts of 44 patients who were admitted to the centre between 2007 and 2012.

Results: All cases except one were caused by pituitary adenomas (61.4% macroadenomas, and 29.5% microadenomas). The most common co-morbidities were nodular thyroid disease (86.4%), hypertension (86.4%), and IGT or type 2 DM (45.5%). Transsphenoidal operation was applied as the first-line therapy in 65.9% of patients and led to disease remission in 48.3%. Primary medical therapy was administered in 25.0% of cases. Of surgically treated patients, 51.7% were diagnosed with desease recurrence and received medical therapy with somatostatin analogs, cabergoline or bromocriptine. Radiotherapy as a third-line treatment was applied in the 17.2% of patients. Based on the latest GH and IGF1 results, the outcomes were: 38.1% controlled, 28.6% partially controlled, and 33.3% uncontrolled. Control and partial control were achieved in 18.2 and 27.3% of cases in primary medical therapy group, and in 13.3 and 40.0% of cases in combined therapy group. Mean observational period IGF1 in the primary medical treatment group (672.8±206.4 μg/l) was not statistically different from combined treatment group (556.4±259.4 μg/l, P=0.139). We observed stronger correlation of IGF1 and GH in samples taken without medical therapy (rs=0.667) than in those taken while on SSA treatment (rs=0.416). GH, gender and age, but not SSA treatment, were significant determinants of IGF1 level in regression analysis.

Conclusions: Control of the disease remains a challenge despite availability of transsphenoidal surgery, SSA, dopamine agonists and conventional radiotherapy. The influence of SSA on IGF1 level remains to be further studied.

Article tools

My recent searches

No recent searches.